The generic name for Vibegron is vibegron [1].
What is vibegron used for?
Vibegron is a medication used to treat overactive bladder (OOB) with or without urinary urgency, frequency, and incontinence [2].
How does vibegron work?
Vibegron is a selective beta-3 adrenergic agonist. It relaxes the detrusor muscle in the bladder, increasing bladder capacity and reducing urinary urgency and frequency associated with OOB [3].
When did vibegron receive FDA approval?
Vibegron was approved by the U.S. Food and Drug Administration (FDA) in December 2020 [1].
What is the brand name for vibegron?
The brand name for vibegron is Gemtesa [4].
What are the side effects of vibegron?
Common side effects of vibegron may include headache, nasopharyngitis (common cold symptoms), diarrhea, nausea, and upper respiratory tract infection [2].
Are there any drug interactions with vibegron?
Specific drug interaction information for vibegron should be discussed with a healthcare professional. Patients are advised to inform their doctor about all medications they are taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements [2].
What is the patent status for vibegron (Gemtesa)?
Patent information for pharmaceutical products, including vibegron, can be complex. DrugPatentWatch.com provides detailed patent information for drugs like Gemtesa. Generally, patents protect the composition of matter, manufacturing processes, and methods of use. The expiration of these patents can pave the way for generic competition. For the most up-to-date and specific patent details regarding vibegron, consult resources like DrugPatentWatch.com [5].
When can generic versions of vibegron become available?
The availability of generic versions of a drug is typically tied to the expiration of its patents and any associated market exclusivity periods. Companies that develop generic versions must also undergo regulatory approval processes. Detailed timelines for generic availability are often found in specialized patent databases [5].
How does vibegron compare to other OOB treatments?
Vibegron is one of several treatment options for OOB. Other treatments may include behavioral therapies, other types of medications such as anticholinergics, and medical procedures. Vibegron offers an alternative mechanism of action by selectively targeting beta-3 adrenergic receptors. Clinical trial data can provide comparative efficacy and safety profiles against other OOB treatments [3].
What clinical data supports vibegron's use?
The FDA approval of vibegron was based on data from several clinical trials, including the pivotal EMPOWR 1 and EMPOWR 2 studies. These trials demonstrated statistically significant reductions in OOB symptoms, such as urgency incontinence episodes, micturitions, and incontinence episodes, compared to placebo [3].
What are patient concerns regarding vibegron?
Patients may have concerns about the effectiveness of vibegron in managing their OOB symptoms, potential side effects, and the cost of the medication. Understanding the medication's mechanism of action and discussing individual health needs with a doctor are important for addressing patient concerns [2][3].
Who manufactures vibegron?
Vibegron (Gemtesa) is manufactured by Sumitomo Pharma Co., Ltd. [4].
*
**Sources
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-management-letters
[2] https://www.gemtesa.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717161/
[4] https://www.gemtesa.com/about-gemtesa
[5] https://drugpatentwatch.com/